Cost–benefit analysis of the National Immunization Program in Spain
Alberto Pérez María Fernández Prada Natalia Cassinello Laura Amanda Vallejo-Aparicio Andrea García Almudena González Ana Durán Néboa Zozaya Irene Fernández Mathilde Daheron Álvaro Hidalgo Ekkehard Beck Antonio García Ruiz a Management,Hospital Nuestra Señora De Sonsoles (Complejo Asistencial De Avila),Ávila,Spainb Preventive Medicine and Public Health,Hospital Vital Alvarez Buylla,Asturias,Spainc Financial and Accounting Management,Universidad Pontificia Comillas,Madrid,Spaind Market Access,GSK,Madrid,Spaine Health Economics and Market Access,Vivactis Weber,Madrid,Spainf Weber Foundation,Madrid,Spaing University of Castilla La Mancha,Toledo,Spainh Value Evidence and Outcomes,GSK,Wavre,Belgiumi IBIMA Platform Bionand,Universidad de Málaga – IBIMA Platform Bionand,Málaga,SpainAlberto Pérez,doctor in medicine,specialist in Preventive Medicine and Public Health,has 15 years of experience in Public health,Vaccines,and Health economics,with background in Public Health Administration and Hospital Management with a master's degree in Economic Evaluation of Health Interventions,Public Health and Health Management.María Fernández Prada is PhD in Preventative Medicine and Public Health and a master's degree in Biomedicine by Granada University in Spain,with a Vaccine Expert title by Complutense University. She is an associate professor in Health Sciences at the University of Oviedo,and part of the Spanish Association of Vaccinology since 2017. She has more than 50 publications on vaccines and patient's safety areas.Natalia Cassinello has a PhD in Business Administration and an executive master's in Behavioral Economics from LSE. Professor of Finance and co-director of the Asset Management Chair at Universidad Pontificia Comillas at Madrid Campus. Her lines of research include Health Economics,Behavioral Economics,and Sustainability.Laura Amanda Vallejo-Aparicio has more than 10 years of experience in health economics and outcomes research,market access and pricing fields,with background in Economics specialized in Public Economics,with master's degrees in Pharmacoeconomics and Market Access and in Epidemiology and Public Health.Andrea Garcia has an MBA and a master's in Health Economics and Pharmacoeconomics. She is employed by GSK,with experience in market access and public health in the vaccines area and with publications in health economics and health technology assessments.Almudena González has more than 10 years of experience in health economics. She is a statistician and has a master's degree in Economic Evaluation of Health Interventions. She currently heads the Health Economics & Market Access department at Weber and is the author of several publications in health economics.Ana Durán has 5 years of experience in health economics,with a background in Business and Administration and a master's degree in Economic Evaluation of Health Interventions and Pharmaceutical Policy.Néboa Zozaya is a health economist with a PhD in economics. She currently heads the Health Affairs and Policy Research department at Weber. She has more than 10 years of experience in the field of health economics and has multiple publications in this field.Irene Fernández has 3 years of experience in Health Affairs and Policy Research,with a background in Pharmacy and Biotechnology and a Master's in Economic Evaluation of Health Interventions and Pharmaceutical Policy.Mathilde Daheron has 3 years of experience in health economics,with a background in Biomedicine and a master's degree in public health.Álvaro Hidalgo is PhD in Economics. Professor of the Area of Fundamentals of Economic Analysis of the UCLM at the Toledo Campus,director of the Research Group in Health Economics and Health Management of the University of Castilla-La Mancha (UCLM). He is President of the Weber Foundation. His lines of research include health economics,health technology assessment,drug economics,patient-reported health outcomes,and health information systems.Ekkehard Beck holds a PhD in Industrial Engineering and Management Sciences from Northwestern University. He is a Health Economics and Outcomes Research leader with over 10 years experience in pharmaceutical industry at Moderna and GSK,consulting and academia. His research interests include how the broader socioeconomic Value of Vaccination can be captured in Vaccines policy decision making and health economic analysis.Antonio J García Ruiz (MD,PhD,MsC) is a Postdoctoral Fellow at the Istituto di Ricerche Farmacologiche "Mario Negri",Milan (Italy). Corresponding member of the Royal Academy of Medicine and Surgery of Granada since 2009. Director of the Official Master in Health Economics,Health Management and Rational Use of Medicines accredited by the National Agency for Quality Assessment and Accreditation (NAQAA) from 2009 to the present. He has supervised 35 Doctoral Theses,and published more than 75 articles related to his field of work (Health Economics,Pharmacoeconomics,Health-Related Quality of Life and evaluation of Health Outcomes) in journals indexed in JCR. He belongs to the CTS-232 and CTS-649 research groups and is a researcher in the Clinical and Economic Evaluation group of the Biomedical Research Institute of Malaga. He has coordinated and participated in more than 30 projects related to health economics and pharmacoeconomics in the field of public and private collaboration,as well as participating in more than 10 competitive public projects through the Office for the Transfer of Research Results of the University of Malaga.
DOI: https://doi.org/10.1080/21645515.2024.2385175
2024-08-22
Human Vaccines & Immunotherapeutics
Abstract:Broad benefits of vaccination programs are well acknowledged but difficult to measure, especially when considering all vaccines included in a National Immunization Program (NIP). The aim was to conduct a cost–benefit analysis of the entire NIP in Spain, and an expanded NIP including four potential additional programs. A cost–benefit analysis was performed in Excel to assess the economic and health benefits (€) of vaccinating a single cohort of newborns over a lifetime horizon compared to no vaccination, from a societal perspective: firstly, according to the 2020 NIP in Spain (including 2021 recommendation for herpes zoster in 65-year-olds); and secondly, with an expanded NIP (adding rotavirus and meningococcal B in infants, and pertussis booster in adults aged >65 years and herpes zoster in all adults >50 years). The main inputs were taken from published literature and Spanish databases. Results were presented as a benefit–cost ratio (economic benefit per €1 invested). A cohort of 343,126 newborns were included in the analysis. The total investment needed to vaccinate the cohort throughout their lifetime, according to the 2020 NIP and the expanded NIP, was estimated at €168.5 million and €275.5 million, respectively. Potential economic benefits were €772.2 million and €803.0 million, respectively. The societal benefit–cost ratio was €4.58 and €2.91 per €1 invested, respectively. Even with the addition of new vaccination programs, the Spanish NIP yielded positive benefit–cost ratios from the societal perspective, demonstrating that NIPs spanning the full life course are an efficient public health measure.
immunology,biotechnology & applied microbiology